甲状腺功能亢进合并烟雾病发病机制的研究进展

doi:10.3969/j.issn.1673-5765.2023.03.015

摘要/Abstract

摘要： 烟雾病是一种以双侧颈内动脉末端及大脑前动脉、大脑中动脉起始部慢性进行性狭窄或闭塞为特征，并继发颅底异常血管网形成的脑血管疾病。甲状腺功能亢进继发烟雾病的发病机制尚不清楚，可能与甲状腺功能、免疫与炎症、遗传因素等有关。免疫和炎症相关的分子变化对血管内皮细胞和平滑肌细胞的影响，可能在颅内大动脉狭窄、闭塞和烟雾血管的形成中起着重要作用。本文对甲状腺功能亢进继发烟雾病的可能病理生理学机制、免疫与炎症、遗传因素等发病机制进行综述。

文章导读： 本文对甲状腺功能亢进继发烟雾病的发病机制进行综述，对免疫与炎症相关的分子机制的研究可能会进一步阐释烟雾血管的形成。

关键词: 烟雾病; 烟雾综合征; 甲状腺功能亢进; 发病机制

Abstract: Moyamoya disease is a kind of cerebrovascular disease characterized by chronic progressive stenosis or occlusion at the end of bilateral internal carotid arteries and the beginning of anterior cerebral arteries and middle cerebral arteries, followed by abnormal vascular network formation at the skull base. The pathogenesis of moyamoya disease secondary to hyperthyroidism is still unclear, and may be related to the thyroid function, immunity and inflammation, and genetic factors. The effects of immunity and inflammation related molecular changes on vascular endothelial cells and smooth muscle cells, may play a key role in the formation of moyamoya vessels and large intracranial artery stenosis and occlusion. This paper summarized the pathogenesis of moyamoya disease secondary to hyperthyroidism by reviewing the available literature.

Key words: Moyamoya disease; Moyamoya syndrome; Hyperthyroidism; Pathogenesis

刘成龙, 张谦, 赵继宗. 甲状腺功能亢进合并烟雾病发病机制的研究进展[J]. 中国卒中杂志, 2023, 18(03): 353-358.

LIU Chenglong, ZHANG Qian, ZHAO Jizong.

Progress of Pathogenesis of Hyperthyroidism Complicated with Moyamoya Disease

[J]. Chinese Journal of Stroke, 2023, 18(03): 353-358.

参考文献

[1] NOMURA S，AKAGAWA H，YAMAGUCHI K，et al. Rare and low-frequency variants in RNF213 confer susceptibility to moyamoya syndrome associated with hyperthyroidism[J/OL]. World Neurosurg，2019，127：e460-e466[2022-05-05]. https://doi.org/10.1016/j.wneu.2019.03.172.
[2] ISHISAKA E，WATANABE A，MURAI Y，et al. Role of RNF213 polymorphism in defining quasi-moyamoya disease and definitive moyamoya disease[J/OL]. Neurosurg Focus，2021，51（3）：E2[2022-05-05]. https://doi.org/10.3171/2021.5. FOCUS21182.
[3] SUBEKTI I，PRAMONO L A. Current diagnosis and management of Graves' disease[J]. Acta Med Indones，2018，50（2）：177-182.
[4] KURODA S，FUJIMURA M，TAKAHASHI J，et al. Diagnostic criteria for moyamoya disease -2021 revised version[J]. Neurol Med Chir（Tokyo），2022，62（7）：307-312.
[5] COLLERAN K M，RATLIFF D M，BURGE M R. Potential association of thyrotoxicosis with vitamin B and folate deficiencies，resulting in risk for hyperhomocysteinemia and subsequent thromboembolic events[J]. Endocr Pract，2003，9（4）：290-295.
[6] NAKAMURA H，SATO K，YOSHIMURA S，et al. Moyamoya disease associated with Graves' disease and down syndrome：a case report and literature review[J/OL]. J Stroke Cerebrovasc Dis，2021，30（1）：105414[2022-05-05]. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105414.
[7] GE P C，ZHANG Q，YE X，et al. Modifiable risk factors associated with moyamoya disease：a case-control study[J]. Stroke，2020，51（8）：2472-2479.
[8] GANESH B B，BHATTACHARYA P，GOPISETTY A，et al. Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity[J]. J Interferon Cytokine Res，2011，31（10）：721-731.
[9] REN S C，GAO B Q，YANG W L，et al. Von Willebrand factor and coagulation factor Ⅷ in moyamoya disease associated with Graves' disease：a case report[J]. Exp Ther Med，2016，12（5）：3195-3200.
[10] POPŁAWSKA-KITA A，SZELACHOWSKA M，MODZELEWSKA A，et al. Endothelial dysfunction in Graves' disease[J]. Adv Med Sci，2013，58（1）：31-37.
[11] TENDLER B E，SHOUKRI K，MALCHOFF C，et al. Concurrence of Graves' disease and dysplastic cerebral blood vessels of the moyamoya variety[J]. Thyroid，1997，7（4）：625-629.
[12] HIDAKA M，OSAKI M，YAMAGUCHI S，et al. Fluctuations in moyamoya vasculopathy associated with basedow disease depending on thyroid hormone status[J]. Case Rep Neurol，2020，12（2）：140-147.
[13] OGAWA S，SATO D，TORAZAWA S，et al. Acute thrombectomy for contralateral internal carotid artery occlusion after revascularization surgery for quasi-moyamoya disease：a case report[J]. NMC Case Rep J，2021，8（1）：673-679.
[14] 葛安岩，丁晶，汪昕. 甲状腺疾病与缺血性脑卒中发病关系的研究进展[J]. 国际神经病学神经外科学杂志，2019，46（1）：117-121.
[15] SMITH T J，HEGEDÜS L. Graves' disease[J]. N Engl J Med，2016，375（16）：1552-1565.
[16] LI H，ZHANG Z S，DONG Z N，et al. Increased thyroid function and elevated thyroid autoantibodies in pediatric patients with moyamoya disease：a case-control study[J]. Stroke，2011，42（4）：1138-1139.
[17] WENG L H，CAO X，HAN L J，et al. Association of increased Treg and Th17 with pathogenesis of moyamoya disease[J/OL]. Sci Rep，2017，7（1）：3071[2022-05-05]. https://doi.org/10.1038/s41598-017-03278-8.
[18] LANTERNA L A，GALLIANI S，ZANGARI R，et al. Thyroid autoantibodies and the clinical presentation of moyamoya disease：a prospective study[J]. J Stroke Cerebrovasc Dis，2018，27（5）：1194-1199.
[19] TANAKA M，SAKAGUCHI M，YAGITA Y，et al. Thyroid antibodies are associated with stenotic lesions in the terminal portion of the internal carotid artery[J]. Eur J Neurol，2014，21（6）：867-873.
[20] HEINK S，YOGEV N，GARBERS C，et al. Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic Th17 cells[J]. Nat Immunol，2017，18（1）：74-85.
[21] KANG H S，KIM J H，PHI J H，et al. Plasma matrix metalloproteinases，cytokines and angiogenic factors in moyamoya disease[J]. J Neurol Neurosurg Psychiatry，2010，81（6）：673-678.
[22] SAKAMOTO S，KIURA Y，YAMASAKI F，et al. Expression of vascular endothelial growth factor in dura mater of patients with moyamoya disease[J]. Neurosurg Rev，2008，31（1）：77-81.
[23] PARK Y S，JEON Y J，KIM H S，et al. The role of VEGF and KDR polymorphisms in moyamoya disease and collateral revascularization[J/OL]. PLoS One，2012，7（10）：e47158[2022-05-05]. https://doi. org/10.1371/journal.pone.0047158.
[24] HAARMANN A，NOWAK E，DEIß A，et al. Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin α-4-transduced outside-in signalling[J]. Acta Neuropathol，2015，129（5）：639-652.
[25] PIGOTT R，DILLON L P，HEMINGWAY I H，et al. Soluble forms of E-selectin，ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells[J]. Biochem Biophys Res Commun，1992，187（2）：584-589.
[26] SORIANO S G，COWAN D B，PROCTOR M R，et al. Levels of soluble adhesion molecules are elevated in the cerebrospinal fluid of children with moyamoya syndrome[J]. Neurosurgery，2002，50（3）：544-549.
[27] ITO H，YOKOI S，YOKOYAMA K，et al. Progressive stenosis and radiological findings of vasculitis over the entire internal carotid artery in moyamoya vasculopathy associated with Graves' disease：a case report and review of the literature[J/OL]. BMC Neurol，2019，19（1）：34[2022-05-05]. https://doi.org/10.1186/s12883-019-1262-1.
[28] MIKAMI T，SUZUKI H，KOMATSU K，et al. Influence of inflammatory disease on the pathophysiology of moyamoya disease and quasi-moyamoya disease[J]. Neurol Med Chir（Tokyo），2019，59（10）：361-370.
[29] FUJIMURA M，FUJIMURA T，KAKIZAKI A，et al. Increased serum production of soluble CD163 and CXCL5 in patients with moyamoya disease：involvement of intrinsic immune reaction in its pathogenesis[J/OL]. Brain Res，2018，1679：39-44[2022-05-05]. https://doi.org/10.1016/j.brainres. 2017.11.013.
[30] LIN R H，XIE Z Y，ZHANG J F，et al. Clinical and immunopathological features of moyamoya disease[J/OL]. PLoS One，2012，7（4）：e36386[2022-05-05]. https://doi.org/10.1371/journal.pone.0036386.
[31] TASHIRO R，NIIZUMA K，KHOR S S，et al. Identification of HLA-DRB1*04：10 allele as risk allele for Japanese moyamoya disease and its association with autoimmune thyroid disease：a case-control study[J/OL]. PLoS One，2019，14（8）：e0220858[2022-05-05]. https://doi.org/10.1371/journal.pone.0220858.
[32] ZHANG Q，LIU Y P，YU L B，et al. The association of the RNF213 p. R4810K polymorphism with quasi-moyamoya disease and a review of the pertinent literature[J/OL]. World Neurosurg，2017，99：701-708，e1[2022-05-05]. https://doi.org/10.1016/j.wneu. 2016.12.119.
[33] KAMADA F，AOKI Y，NARISAWA A，et al. A genome-wide association study identifies RNF213 as the first moyamoya disease gene[J]. J Hum Genet，2011，56（1）：34-40.
[34] CARITHERS L J，ARDLIE K，BARCUS M，et al. A novel approach to high-quality postmortem tissue procurement：the GTEx project[J]. Biopreserv Biobank，2015，13（5）：311-319.
[35] LIU J S，JUO S H，CHEN W H，et al. A case of Graves' diseases associated with intracranial moyamoya vessels and tubular stenosis of extracranial internal carotid arteries[J]. J Formos Med Assoc，1994，93（9）：806-809.
[36] KAMASAKI H，TAKEUCHI T，MIKAMI T，et al. A case of Graves' disease diagnosed in the course of bilateral carotid artery stenoses（moyamoya disease）; a case report and review of the literature[J]. Clin Pediatr Endocrinol，2013，22（3）：39-44.
[37] TOKIMURA H，TAJITSU K，TAKASHIMA H，et al. Familial moyamoya disease associated with Graves' disease in a mother and daughter. Two case reports[J]. Neurol Med Chir（Tokyo），2010，50（8）：668-674.
[38] YAMAUCHI T，TADA M，HOUKIN K，et al. Linkage of familial moyamoya disease（spontaneous occlusion of the circle of Willis）to chromosome 17q25[J]. Stroke，2000，31（4）：930-935.